CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionReturn on equity is -214.5%, lower than 95% of its Biotechnology peers (median -21.7%)
- FinancialsAltman Z-Score 1.39: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.48BCNY517.04M · vs all stocks (USD)
Revenue (TTM)
470.43MCNY69.87M · vs all stocks (USD)
Profit Margin
-15.60%vs Biotechnology peers
Beta
0.7930xvs all stocks
52-Week Change
-22.22%vs all stocks
Market Capitalization
3.48BCNY517.04M · vs all stocks (USD)
Enterprise Value
4.10BCNY608.85M · vs all stocks (USD)
Price to Sales (TTM)
7.82xvs Biotechnology peers
Price to Book (MRQ)
51.82xvs Biotechnology peers
Enterprise to Revenue
8.71xvs Biotechnology peers
Enterprise to EBITDA
99.11xvs Biotechnology peers
Gross Margin
18.45%vs Biotechnology peers
Profit Margin
-15.60%vs Biotechnology peers
Operating Margin
1.28%vs Biotechnology peers
Return on Assets (TTM)
-1.58%vs Biotechnology peers
Return on Equity (TTM)
-214.48%vs Biotechnology peers
Revenue (TTM)
470.43MCNY69.87M · vs all stocks (USD)
Revenue per Share (TTM)
3.04CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-21.40%vs Biotechnology peers
Gross Profit (TTM)
58.60MCNY8.70M · vs all stocks (USD)
EBITDA (TTM)
31.57MCNY4.69M · vs all stocks (USD)
Net Income (TTM)
-73.38MCNY-10.90M · vs all stocks (USD)
Operating Cash Flow (TTM)
-55.29MCNY-8.21M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-429.99MCNY-63.86M · vs all stocks (USD)
5-Year Average Dividend Yield
1.24%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
1.75MCNYFY2025 · Dec 31, 2025Revenue
516.58MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
481.95MCNYFY2025 · Dec 31, 2025Gross Profit
34.63MCNYFY2025 · Dec 31, 2025Operating Income
-60.81MCNY-9.03M · vs all stocks (USD)
Pre-tax Income
-138.85MCNYFY2025 · Dec 31, 2025Income Tax Expense
453.79KCNYFY2025 · Dec 31, 2025Net Income
-139.31MCNYFY2025 · Dec 31, 2025EBIT
-85.11MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
31.57MCNYFY2025 · Dec 31, 2025Research & Development
25.60MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
35.20MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.74MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
71.92KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
53.74MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.9000CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.9000CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
154.74MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
154.74MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-139.31MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
43.27KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-86.28MCNYFY2025 · Dec 31, 2025Free Cash Flow
-212.28MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
55.58MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-139.31MCNYFY2025 · Dec 31, 2025Other Non-cash Items
57.31MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
22.59MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-26.87MCNYFY2025 · Dec 31, 2025Capital Expenditures
-126.00MCNYFY2025 · Dec 31, 2025Sale of Investments
1.13MCNYFY2025 · Dec 31, 2025Other Investing Activity
-10.39MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-135.26MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
172.07MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-507.18MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-42.52MCNYFY2025 · Dec 31, 2025Other Financing Charges
573.08MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
195.44MCNYFY2025 · Dec 31, 2025Shares Outstanding
155.42MSharesUpdated Aug 20, 2026Float Shares
61.33MSharesUpdated Aug 20, 2026% Held by Insiders
59.92%vs all stocks
% Held by Institutions
5.00%vs all stocks
Total Cash (MRQ)
51.40MCNY7.63M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3310CNYUpdated Aug 20, 2026Total Debt (MRQ)
469.22MCNY69.69M · vs all stocks (USD)
Total Debt to Equity (MRQ)
6.49xvs Biotechnology peers
Current Ratio (MRQ)
0.3650xvs Biotechnology peers
Book Value per Share (MRQ)
0.4570CNYUpdated Aug 20, 2026Total Assets
748.71MCNY111.20M · vs all stocks (USD)
Total Current Assets
207.68MCNYFY2025 · Dec 31, 2025Total Liabilities
683.78MCNYFY2025 · Dec 31, 2025Total Non-current Assets
541.03MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
86.54MCNYFY2025 · Dec 31, 2025Total Current Liabilities
597.24MCNYFY2025 · Dec 31, 2025Cash
55.58MCNYFY2025 · Dec 31, 2025Cash Equivalents
20.00KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
55.60MCNYFY2025 · Dec 31, 2025Accounts Receivable
42.39MCNYFY2025 · Dec 31, 2025Inventory
95.48MCNYFY2025 · Dec 31, 2025Accounts Payable
102.52MCNYFY2025 · Dec 31, 2025Short-term Debt
329.76MCNYFY2025 · Dec 31, 2025Other Current Liabilities
127.44KCNYFY2025 · Dec 31, 2025Long-term Debt
30.00MCNYFY2025 · Dec 31, 2025Common Stock (Book)
155.42MCNYFY2025 · Dec 31, 2025Retained Earnings
-722.54MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
64.93MCNY9.64M · vs all stocks (USD)
52-Week Low
20.77CNYUpdated Aug 20, 202652-Week High
48.72CNYUpdated Aug 20, 202652-Week Change
-22.22%vs all stocks
Beta
0.7930xvs all stocks
50-Day MA
23.75CNYUpdated Aug 20, 2026200-Day MA
33.92CNYUpdated Aug 20, 2026Avg 10-Day Volume
1.62MSharesUpdated Aug 20, 2026Avg 30-Day Volume
1.85MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.4800CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -214.5%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -2.14Industry median: -0.22Industry P5: -1.66Peers compared: 261
Current ratio is 0.37×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.36Industry median: 5.64Industry P5: 1.06Peers compared: 261
Debt-to-equity is 6.49×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 6.49Industry median: 0.09Industry P95: 0.88Peers compared: 261
Price-to-book is 51.82×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 51.82Industry median: 2.97Industry P95: 23.50Peers compared: 261
Financial Health
Altman Z-Score 1.39: grey zoneSignificant
Altman Z-Score: 1.39
Low earnings qualitySignificant
Earnings Quality Score: -0.82
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zura Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aquestive Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eiken Chemical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aim Vaccine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
IOL Chemicals and Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule